The CNS field has been waiting far too long for a true breakthrough in brain-targeted drug delivery. Despite decades of R&D and countless promising candidates, the blood-brain barrier remains the toughest obstacle standing between innovation and impact.
But that’s finally starting to change.
From GSK’s $2.5B deal with ABL Bio and AbbVie’s $1.4B acquisition of Aliada, to clinical progress from Roche, Denali, and Alnylam, new modalities are redefining what’s possible for CNS therapeutics.
Whether through BBB-bypassing platforms, brain-penetrant antibodies, or direct delivery via CED and focused ultrasound, this momentum is undeniable.
This eBook explores the technologies, partnerships, and translational strategies shaping the next generation of CNS therapies, spotlighting the experts and companies driving this long-awaited transformation.
Inside, you’ll discover:
- How pharma giants and biotechs are tackling brain delivery with novel modalities
- The latest advances in BBB penetration and local delivery platforms
- Real-world case studies from Roche, Denali, Biogen, Ionis, and more
- Insights from 100+ CNS delivery experts across biology, chemistry, and device innovation
Access your free copy to see how the 7th CNS Drug Delivery Summit is accelerating the next wave of brain-targeted therapeutics.
About Hanson Wade Group - 7th CNS Drug Delivery Summit
Welcome to the 7th CNS Drug Delivery Summit
Despite milestones such as Roche’s Trontinemab Brainshuttle™ achieving robust amyloid clearance, challenges remain in reaching targeted brain regions, improving predictive modelling, ensuring efficacy and penetrance, and developing safer, targeted delivery approaches.
Join 100+ industry experts spanning neuroscientists, chemists, device engineers, conjugation scientists, DMPK experts, delivery specialists, and more at the 7th CNS Drug Delivery Summit to collaborate, network, and learn cutting-edge strategies that are tackling the unique challenges in gaining access to the brain.
Gain actionable insights from case studies, presentations, and deep-dive discussions on CNS drug delivery strategies covering systemic and local delivery, blood-brain barrier targeting, RMT modulation, and emerging modalities from Biogen, Sanofi, Merck, UCB, Eli Lilly, Alnylam, Voyager, and more, to advance brain access and accelerate CNS therapy development.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.